Teosyal Rha 4 (2x1,2 ml)

Treatment is strictly contraindicated. No clinical safety data exists for RHA fillers during pregnancy or breastfeeding. We prioritize patient health and defer all aesthetic injections until after the nursing period has concluded.

The formulation contains 23 mg/ml of Resilient Hyaluronic Acid (RHA) cross-linked with a low level of BDDE, and 0.3% Lidocaine hydrochloride for patient comfort.

Dosage is individualized based on the level of volume restoration required. For a full mid-face lift, 1.2 ml per side is common. Practitioners should evaluate if a lighter approach, such as 0.5 ml of filler, is sufficient for minor refinements before utilizing the full density of RHA 4. In cases of extreme jawline definition, it is often compared to the projection power of Juvederm Volux.

Common reactions include temporary redness, tenderness, and localized edema. To manage these effectively, patients should follow our tips on reducing post-injection swelling. Because of its structural density, minor firmness may be felt during the first 14 days. If persistent nodules occur, practitioners may refer to our guide on avoiding filler lumps.

The gel acts as a mechanical support in the deep dermis or fatty tissue. Its unique long-chain matrix allows it to expand and contract with facial muscles. Unlike static gels like Restylane Lyft, RHA 4 prioritizes "resilience," preventing the filler from looking stiff during animation. Proper massage techniques ensure the product integrates seamlessly into the dynamic layers of the face.

Avoid alcohol for 24h before and 48h after the procedure. Alcohol is a vasodilator that can increase blood flow to the deep injection sites, potentially worsening bruising. For more details on behavioral restrictions, consult our expert aftercare guide. In heavy volumizing cases, similar to Teosyal Ultra Deep, minimizing inflammation is key to a smooth result.